635 related articles for article (PubMed ID: 26020065)
21. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Bumma N; Papadantonakis N; Advani AS
Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
[TBL] [Abstract][Full Text] [Related]
22. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
23. Targeting non-Hodgkin lymphoma with blinatumomab.
Sanders S; Stewart DA
Expert Opin Biol Ther; 2017 Aug; 17(8):1013-1017. PubMed ID: 28532177
[TBL] [Abstract][Full Text] [Related]
24. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
25. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
Meckler JF; Levis DJ; Vang DP; Tuscano JM
Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
[TBL] [Abstract][Full Text] [Related]
26. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
27. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
Algeri M; Del Bufalo F; Galaverna F; Locatelli F
Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
29. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
30. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
[TBL] [Abstract][Full Text] [Related]
32. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.
Lau KM; Saunders IM; Goodman AM
J Oncol Pharm Pract; 2021 Jun; 27(4):821-826. PubMed ID: 32605497
[TBL] [Abstract][Full Text] [Related]
33. Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.
Alcharakh M; Yun S; Dong Y; Vincelette ND; Daud M; Manzoor S; Riaz IB; Anwer F
Immunotherapy; 2016 Jul; 8(8):847-52. PubMed ID: 27381683
[TBL] [Abstract][Full Text] [Related]
34. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A
Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783
[TBL] [Abstract][Full Text] [Related]
35. A review of blinatumomab, a novel immunotherapy.
Newman MJ; Benani DJ
J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
[TBL] [Abstract][Full Text] [Related]
36. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
[TBL] [Abstract][Full Text] [Related]
37. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
38. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
[TBL] [Abstract][Full Text] [Related]
39. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
